Frances C D, Noguchi H, Massie B M, Browner W S, McClellan M
Veterans Affairs Medical Center (111A1), 4150 Clement St, San Francisco, CA 94121, USA.
Arch Intern Med. 2000 Sep 25;160(17):2645-50. doi: 10.1001/archinte.160.17.2645.
Angiotensin-converting enzyme (ACE) inhibitors have been shown to decrease mortality in patients with myocardial infarction and depressed left ventricular function, but physicians may be reluctant to prescribe ACE inhibitors to patients with concomitant renal insufficiency.
To evaluate whether patients with depressed left ventricular ejection fraction following acute myocardial infarction have a similar reduction in mortality from ACE inhibitors regardless of their renal function.
Retrospective cohort study using medical record data.
All nonfederal acute care hospitals.
A cohort of 20,902 Medicare beneficiaries aged 65 years and older directly admitted to the hospital from February 1, 1994, through July 30, 1995, and with a documented left ventricular ejection fraction of less than 40% measured by echocardiography, radionuclide scintigraphy, or angiography following a confirmed acute myocardial infarction.
One-year survival for patients who received or who did not receive an ACE inhibitor at hospital discharge, stratified by the patient's level of renal function.
For the entire cohort, the receipt of an ACE inhibitor on hospital discharge was associated with greater 1-year survival (hazards ratio, 0.84; 95% confidence interval, 0.77-0.91) after adjusting for patient demographic characteristics, comorbidity, severity of illness (including left ventricular ejection fraction), and the receipt of other therapies. In stratified models, the receipt of an ACE inhibitor was associated with a 37% (16%-52%) lower mortality for patients who had poor renal function (serum creatinine level,<265 micromol/L [<3 mg/dL]) and a 16% (8%-23%) lower mortality for patients who had better renal function. Use of aspirin therapy attenuated the benefit of ACE inhibitors in patients with poor renal function.
Moderate renal insufficiency should not be considered a contraindication to the use of ACE inhibitors in patients with depressed left ventricular ejection fraction following myocardial infarction. Use of aspirin therapy may attenuate the benefit of ACE inhibitors in patients with high serum creatinine levels; therefore, further studies are needed to determine whether treatment with aspirin, alternative antiplatelet agents, or anticoagulation is indicated for these patients.
血管紧张素转换酶(ACE)抑制剂已被证明可降低心肌梗死和左心室功能不全患者的死亡率,但医生可能不愿给合并肾功能不全的患者开ACE抑制剂。
评估急性心肌梗死后左心室射血分数降低的患者,无论其肾功能如何,使用ACE抑制剂后死亡率是否有类似降低。
利用病历数据进行回顾性队列研究。
所有非联邦急症护理医院。
一组20902名年龄在65岁及以上的医疗保险受益人,于1994年2月1日至1995年7月30日直接入院,在确诊急性心肌梗死后,通过超声心动图、放射性核素闪烁扫描或血管造影记录左心室射血分数低于40%。
出院时接受或未接受ACE抑制剂治疗的患者的1年生存率,按患者肾功能水平分层。
在对患者人口统计学特征、合并症、疾病严重程度(包括左心室射血分数)和其他治疗的接受情况进行调整后,对于整个队列,出院时接受ACE抑制剂治疗与1年生存率更高相关(风险比,0.84;95%置信区间,0.77 - 0.91)。在分层模型中,肾功能较差(血清肌酐水平<265微摩尔/升[<3毫克/分升])的患者接受ACE抑制剂治疗后死亡率降低37%(16% - 52%),肾功能较好的患者死亡率降低16%(8% - 23%)。阿司匹林治疗的使用减弱了ACE抑制剂对肾功能较差患者的益处。
中度肾功能不全不应被视为心肌梗死后左心室射血分数降低患者使用ACE抑制剂的禁忌证。阿司匹林治疗的使用可能会减弱ACE抑制剂对血清肌酐水平高的患者的益处;因此,需要进一步研究以确定这些患者是否需要使用阿司匹林、替代抗血小板药物或抗凝治疗。